Does NMN Help With Hot Flushes?

Hot flushes are usually treated as a hormone problem, and for good reason: they track the fall in oestrogen that defines the menopausal transition. But in 2026 a small clinical trial tested a different lever entirely. Instead of replacing the hormone, the researchers tried to top up the cell's energy molecule, NAD+, and watched what happened to flushes, sleep and the balance of a woman's own oestrogens. The result was more interesting than a study this size has any right to be, and it points to a mechanism that any good NAD+ booster shares.

The trial was run by Holmes and colleagues and published in Frontiers in Aging in 2026¹. It is worth being upfront about what was tested and by whom: a commercial NR-plus-pterostilbene supplement (marketed as Basis by Elysium Health), in a study involving that manufacturer. That does not invalidate the finding, but it is the context to read it in. Forty healthy women over the age of 35 took a daily combination of NR (nicotinamide riboside, 250mg) and pterostilbene (50mg) for seven days. Thirty-two of them self-reported symptoms of the menopause transition; the other eight did not, and acted as an internal comparison group. The researchers logged a menopausal symptom survey before and after, and collected urine to measure the two main oestrogens, oestrone (E1) and oestradiol (E2), along with markers of NAD+ turnover.

By the end of the week, the symptomatic group reported significant decreases in the frequency and magnitude of hot flushes, bloating and poor sleep, while the women without symptoms showed no meaningful change. The biochemical finding sat neatly alongside the symptom data: a significant increase in the oestradiol-to-oestrone ratio, meaning the body had shifted some of its oestrogen towards the more active form. The supplement also raised the expected urinary markers of NAD+ metabolism, confirming the women were absorbing and using it.

This was not the first time this NR-plus-pterostilbene combination had been studied. An earlier randomised, placebo-controlled trial of the same branded combination in adults aged 60 to 80 showed it raised whole-blood NAD+ by roughly 40 to 90% above baseline, dose-dependently and safely². So the menopause pilot was testing a combination already known to do what it claims at the cellular level. The new question was whether that cellular change would translate into fewer hot flushes, and the early answer was yes.

The proposed mechanism is elegant, and it runs entirely through NAD+. Raising NAD+ also raises a closely related molecule, NADPH. NADPH is the cofactor an enzyme called 17-beta-hydroxysteroid dehydrogenase needs to convert oestrone, the weaker oestrogen that dominates after menopause, into oestradiol, the more active form. More NAD+ means more NADPH, which means the enzyme can nudge a woman's oestrogen balance back towards oestradiol. That is exactly the shift the trial measured, and it is a coherent explanation for why a molecule with no hormone in it might still soften a hormonal symptom¹.

There is a second strand to the story. Oestrogen and a longevity enzyme called SIRT1 are linked: oestrogen is proposed to support SIRT1 activity, and SIRT1 in turn depends on NAD+ as its fuel³. When oestrogen falls at menopause, SIRT1's support falls with it, at the same time as NAD+ is declining for unrelated reasons. Topping up NAD+ does not replace oestrogen, but it does refill the fuel that the oestrogen-linked repair machinery runs on. The hot flush is the visible symptom; underneath it is a cell that has lost both a hormone and an energy molecule at once.

The reason this approach makes sense is that the NAD+ decline is real and measurable, not theoretical. Direct measurements in human tissue show NAD+ falling steadily across adult life⁴. By the time a woman reaches her perimenopausal years, her cells are running on noticeably less of the molecule that powers their energy and repair work⁵.

Part of that decline is faster destruction. An enzyme called CD38 consumes NAD+, and its activity climbs with the low-grade inflammation of midlife⁶. So NAD+ is being made more slowly and broken down more quickly at the same time. Menopause lands on top of this cellular shortfall rather than causing it from scratch, which is why a strategy aimed at the NAD+ system, rather than at any single symptom, is worth taking seriously.

The trial used NR, so it is fair to ask whether the benefit is specific to that one precursor. The honest answer is that it almost certainly is not. NR and NMN are both precursors that feed into the same salvage pathway and raise the same intracellular NAD+ pool. NMN has its own human evidence that it lifts blood NAD+ safely and dose-dependently in healthy adults^{7 8}, and a placebo-controlled trial in postmenopausal women found NMN improved muscle insulin sensitivity with measurable rises in NAD+⁹.

Because the hot flush mechanism is driven by NAD+ itself, and not by which molecule delivered it, the rationale from the NR study extends to an NMN-based booster. The one honest caveat is that no trial has yet run the same seven-day hot flush test using NMN specifically, so this is a mechanism-based expectation rather than a separately proven result. It is the same reasoning, applied to the same cellular target.

The Repair is For Youth's lead NAD+ formula. Each capsule contains 450mg of NMN (as Uthever™), 50mg of apigenin (as ApiAge® Apigenin) and 50mg of pterostilbene. It is designed to support the NAD+ system at three points: NMN supplies the NAD+ precursor, apigenin helps limit CD38 breakdown, and pterostilbene, the same compound paired with NR in the study, supports the activation side through SIRT1.